China's Country Garden indicates default, warns of difficulty in meeting debt obligations
By P.R. Venkat
Country Garden Holdings (HK:2007) warned that it wouldn't be able to meet all its offshore payment obligations on time as the Chinese property developer struggles to raise cash with sales spiralling lower.
The company said Tuesday that it "faces significant uncertainty regarding asset disposals, and its liquidity position is expected to remain very tight in the short- to medium-term."
It said that it hadn't made a 470.0 million Hong Kong dollar (US$60.0 million) payment and more non-payments could lead to creditors demanding accelerated payments or taking enforcement action.
China's property sector has been severely stressed recently due to falling property sales and weak consumer confidence. This downturn has led to defaults by several developers, including debt-laden China Evergrande Group (HK:3333) and Sunac China Holdings (HK:1918).
On Monday, bond investors said that Evergrande's 11th-hour cancellation of a restructuring affecting more than US$19 billion worth of international debt could lead to a messy collapse and have "a catastrophic effect" on the sector.
Country Garden said Tuesday that in the first nine months of the year, its contracted property sales fell about 44% on year to 154.98 billion yuan (US$21.25 billion).
Available funds are depleted and its sales and financing remain under pressure, the developer added. Due to current market conditions, it will be hard to generate cash via asset sales, it said.
"Consequently, the group's cash position remains under significant pressure," it said.
Country Garden has tapped China International Capital and Houlihan Lokey as financial advisors to help evaluate the group's capital structure and liquidity.
"The company will actively pursue offshore liability management measures and develop a holistic solution in a fair and equitable manner to achieve a sustainable capital structure," it said.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-09-23 2214ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing